Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization.  Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.

(Photo: http://photos.prnewswire.com/prnh/20121213/CG29278)

MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome.  VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026.   The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.

Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.  

About Raynaud's Disease
An estimated 9-11 million people in the United States suffer from Raynaud's Disease, 2.1 million of which have been diagnosed and are seeking medical treatment. Raynaud's patients can experience severe pain associated with chronic vasospasm episodes in their hands, feet and other extremities.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprie
'/>"/>

SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... herpes simplex -- might increase the risk of Alzheimer,s disease, ... a carrier of certain antibodies to the virus can double ... "The identification of a treatable cause [herpes simplex] of the ... Dr. Hugo Lovheim, an associate professor in the department of ...
(Date:10/25/2014)... News) -- Researchers who discovered antibiotics in farmed ... for concern. The use of antibiotics in ... consumption contribute to the development of antibiotic-resistant bacteria ... from the study. Each year in the ... people and kill about 23,000, according to the ...
(Date:10/25/2014)... News) -- Current osteoporosis screening guidelines and tools ... risk for osteoporosis-related fractures, a new study says. ... need tools that help us accurately predict who ... can target these at-risk people for preventive measures," ... in the division of general internal medicine and ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... Nutraceutics(TM) announces the addition of Jim and Julie ... marketing professionals. Their remarkable achievements and expertise are ... of worldwide, home-based business owners. Former Amway Quixtar ... throughout an impressive 28-year career. Jim and Julie ...
... Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ), ... commercialization of proprietary products that address important therapeutic needs ... of Joseph T. Kennedy to the position of Vice ... Mr. Kennedy will provide legal advice to the company ...
... Medical Center have joined forces to help provide area ... patient care. This new partnership is a unique program ... better handle the cumbersome and time-consuming issues of managing ... Center will use Physicians Practice,s extensive resources to deliver ...
... Medical Corporation today launched the third in a series ... Bruschi, a professional football player who suffered a stroke ... career. The new video features Tedy describing his personal ... a continuation of Tedy,s story that began with the ...
... Study suggests that fast-growing youth have greater fondness for treats, ... your children will eat only a few bites of dinner ... ice cream? , Blame it on their growing bones. , ... a higher preference for sweets than children growing at a ...
... Earn Decision Resources, Clinical Gold Standard Status for ... New Report from Decision ResourcesWALTHAM, Mass., March 25 ... research and advisory firms for pharmaceutical and healthcare ... therapy,s effect on the rate of mortality is ...
Cached Medicine News:Health News:Former Amway/Quixtar Diamond Leaders Find New Home at Eniva Nutraceutics 2Health News:Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel 2Health News:Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel 3Health News:Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel 4Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 2Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 3Health News:AGA Medical Corporation Launches Third Web-Based Stroke Education and Awareness Video Featuring Professional Football Player Tedy Bruschi 2Health News:AGA Medical Corporation Launches Third Web-Based Stroke Education and Awareness Video Featuring Professional Football Player Tedy Bruschi 3Health News:A Child's Sweet Tooth May Be All in the Bones 2Health News:A Child's Sweet Tooth May Be All in the Bones 3Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 2Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 3
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Smooth colibri tip; In Titanium....
Gently curved 5mm Platform With 12, 0.12mm Teeth; In Titanium....
Angled tip, 0.3mm triangular grasping tips; In Titanium....
Medicine Products: